A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Phase 1 Active not recruiting 30 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy .

Timeline

Start: 2022-11-24
Primary completion: 2025-11-01
Completion: 2026-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadonilimab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Regorafenib	Small molecule	80 mg	Oral

Indications

No indication recorded.